Differentiated Thyroid Cancer
📧 Sign up to get email alerts when something new happens for Differentiated Thyroid Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-05-22Clinical Trial Update: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer [Phase 3]
Phase 3 trial evaluating dabrafenib plus trametinib in previously treated metastatic radioactive iodine-refractory BRAF V600E-positive diffe…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
This clinical trial update reports completion of a study evaluating a thyroglobulin point-of-care assay for rapid detection of metastatic di…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer [Phase 2]
A Phase 2 trial evaluating the combination of MEK inhibitor trametinib and BRAF V600E inhibitor dabrafenib with radioactive iodine in patien…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer [Phase 4]
Phase 4 study evaluating the safety and efficacy of Lenvatinib in patients with refractory differentiated thyroid cancer has completed. The …
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer [Phase 3]
Phase 3 trial evaluating whether prophylactic central neck dissection can modify outcomes in low-risk differentiated thyroid cancer; the stu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Anlotinib and Benmelstobart in DTC [Phase 2]
A Phase 2 clinical trial evaluating the combination of Anlotinib and Benmelstobart for differentiated thyroid cancer is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy [NA]
A prospective study evaluating the safety and efficacy of radiofrequency ablation for metastatic lymph nodes in differentiated thyroid cance…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: IDEntification of New Predisposition Genes in Differentiated THYroid Cancer [NA]
A Nantes University Hospital–led study to identify predisposition genes in differentiated thyroid cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer [Phase 1, Phase 2]
Phase 1 and Phase 2 clinical evaluations of AL2846 Capsule for differentiated thyroid cancer have been completed. The study was sponsored by…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Robotic Surgery Via Bilateral Axillo-breast Approach for Relatively Low-risk Papillary Thyroid Carcinoma With Lateral Cervical Lymph Node Metastasis: a Safe and Effective Cosmetic Procedure in the Context of Prevalent Thyroid Ultrasound Screening
This completed trial evaluates a robotic bilateral axillo-breast approach for relatively low-risk papillary thyroid carcinoma with lateral c…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid Cancer: Insight From Middle Eastern Cohort
This trial update reports no prognostic or molecular disparity between synchronous and metachronous metastases in differentiated thyroid can…
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer [Phase 2]
Phase 2 trial evaluating camrelizumab in combination with apatinib for radioactive iodine-refractory differentiated thyroid cancer; the stud…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer [Phase 1]
Phase 1 trial evaluating astatine-211 targeted alpha therapy for differentiated thyroid cancer by Osaka University. The study status is COMP…
-
CLINICAL_TRIALS trial_result · 2024-03-28Clinical Trial Update: Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal [Phase 3]
A Phase 3 trial comparing rhTSH as an adjunctive diagnostic tool in differentiated thyroid cancer patients post-thyroidectomy versus after t…
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating dose tolerance, pharmacokinetics, and iodine uptake for recombinant human thyroid-stimulating hormone (r…
-
CLINICAL_TRIALS trial_result · 2024-01-12Clinical Trial Update: A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer [Phase 1, Phase 2]
Phase I/II trial of MLN0128 in metastatic anaplastic thyroid cancer and poorly differentiated or radioiodine-refractory differentiated thyro…
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer [Phase 3]
Phase 3 trial comparing high dose versus low dose Iodine-131 with or without rhTSH in differentiated thyroid cancer; current status is unkno…
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer [Phase 3]
Phase 3 clinical trial update evaluating the efficacy and safety of recombinant human TSH (rhTSH) as adjuvant radioiodine ablation therapy i…
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. [Phase 2]
Phase 2 trial update evaluating safety and effectiveness of rhTSH in radioiodine treatment for differentiated thyroid cancer.
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy [Phase 3]
Phase 3 study comparing cabozantinib to placebo in radioiodine-refractory differentiated thyroid cancer after prior VEGFR-targeted therapy; …
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer [Phase 3]
Phase 3 trial update evaluating apatinib for radioactive iodine-refractory differentiated thyroid cancer.
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases [Phase 4]
Phase 4 trial update on the efficacy of Strontium-89 (Sr-89) for differentiated thyroid cancer with bone metastases.
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry [Phase 2]
Phase 2 trial update on optimizing therapy for metastatic differentiated thyroid cancer using 124I PET dosimetry.
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas [Phase 2]
Phase 2 trial evaluating lenvatinib plus denosumab for predominantly bone metastatic radioiodine-refractory differentiated thyroid carcinoma…
-
CLINICAL_TRIALS trial_result · 2022-01-28Clinical Trial Update: Anlotinib or Penpulimab in Combination With RAI for DTC [Phase 2]
Phase 2 clinical trial exploring anlotinib or penpulimab in combination with radioactive iodine for differentiated thyroid cancer.